Triple-Drug attack aims to stop liver cancer recurrence after surgery
NCT ID NCT07682272
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination before and after surgery. The main goal is to see if the treatment shrinks the tumor significantly before surgery, and researchers also track how long people stay cancer-free and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-8068, adebrelimab, and apatinib
- What this could lead to
- If successful, this combination could reduce the chance of liver cancer returning after surgery, offering a new perioperative treatment option.
- What could go wrong
- This is an early-phase trial with a small number of participants. The combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA WITH INTERMEDIATE OR HIGH RECURRENCE RISK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China